COMMUNIQUÉS West-GlobeNewswire

TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer

09/09/2024 - 22:01

SAN MATEO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- TriArm Therapeutics (“TriArm” or the “Company”), a clinical-stage, next-generation cell therapy company leveraging its global presence and core non-viral platform to [...]

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

09/09/2024 - 22:00

TAMPA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the [...]

Recovery First Treatment Center Launches Evening Virtual Treatment Program in English and Spanish, Expanding Access to Care

09/09/2024 - 20:58

HOLLYWOOD, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- As the nation recognizes National Recovery Month, Recovery First Treatment Center has launched a virtual evening Intensive Outpatient Program (IOP) to help more people [...]

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

09/09/2024 - 18:05

81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not [...]

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

09/09/2024 - 17:45

Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR) 1 Preliminary activity in patients with [...]

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

09/09/2024 - 17:01

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted [...]

CorMedix Inc. Announces New Commercial Agreement

09/09/2024 - 16:52

BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today [...]

World-renowned diabetes researcher joins Wendy Novak Diabetes Institute

09/09/2024 - 16:30

Norton Healthcare, Norton Children’s to become a hub for isolating high-quality human islet cells for diabetes research and transplant LOUISVILLE, Ky., Sept. 09, 2024 (GLOBE NEWSWIRE) -- An internationally known [...]

PetVivo Meets Growing Demand for Spryng™ with Appointment of Veterinary Surgeon, Kirsty Husby, as Senior Technical Services Veterinarian

09/09/2024 - 16:22

Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Sept. 09, 2024 (GLOBE [...]

Novo Nordisk A/S - share repurchase programme

09/09/2024 - 16:10

Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]

ADvantage Therapeutics, Inc. Welcomes Dr. William A. Haseltine as Strategic Advisor to Drive Innovation in Alzheimer's Disease Research and Anti-aging Therapies such as Klotho Protein Supplementation to Extend Healthy Human Lifespan

09/09/2024 - 16:01

MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a leading clinical-stage biotechnology company dedicated to the advancement of innovative therapies for Alzheimer's disease, proudly announces the [...]

Novo Nordisk A/S - share repurchase programme

09/09/2024 - 15:55

Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the [...]

Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

09/09/2024 - 15:31

Early Pilot Study Data from Veteran Volunteers is Compelling - Part B JACKSON CENTER, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We [...]

Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference

09/09/2024 - 15:00

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]

T2 Biosystems Provides Updates on its New Product Development Pipeline Progress

09/09/2024 - 15:00

Company plans to launch multiple direct-from-blood diagnostics over the next 15 months for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris LEXINGTON, Mass., Sept. 09, 2024 (GLOBE [...]

Stereotaxis to Present at Upcoming Investor Conferences

09/09/2024 - 14:40

ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and [...]

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

09/09/2024 - 14:30

SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and [...]

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

09/09/2024 - 14:30

SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on [...]

Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA

09/09/2024 - 14:30

Collaboration Aims to Expedite the Development of Critical Solutions for Public Health Threats, Including Pandemic Preparedness and Emerging Infectious Diseases DURHAM, N.C., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scorpius [...]